JPRN-UMIN000051155已完成Unknown
Treatment of Myasthenia Gravis (MG) Focusing on Corticosteroid Dose: An Insurance Claims Database Study in Japan - Treatment pattern on MG
CB Japan Co.,Ltd.0 个研究点目标入组 2,000 人开始时间: 2023年5月25日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 2,000
研究概览
简要总结
- Only about half of MG patients had OCS as an initial treatment and percentages were similar before and after 2014. 2. Achievement rates of OCS below 5mg/day were higher after 2014 than before 2014. 3. Lower doses of OCS (below 5mg/day) were more frequently observed after 2014 than before 2014 in the first 12 weeks.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 16years-old 至 100years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Exclusion criteria will be as described below. - Having any immunotherapy for longer than 90 days during the baseline period until 90 days before the index date - Having a claim with MG treatment recorded any time until 90 days before the index date
研究者
相似试验
招募中
不适用
Initial therapy for myasthenia gravis of combined therapy for tacrolimus and IVIGMyasthenia gravisJPRN-UMIN000015019Kansai medical university20
终止
1 期
Subcutaneous Ig Maintenance Therapy for Myasthenia GravisMyasthenia GravisNCT01828294St. Louis University4
尚未招募
1 期
CIGB-500 in acute myocardial infarction (AMIGOS study)Acute myocardial infarctionRPCEC00000177Center for Genetic Engineering and Biotechnology (CIGB), in Havana20
已完成
4 期
Magnesium Sulphate Injection in Treatment of Myofascial Trigger PointsTrigger Point Pain, MyofascialNCT04742140Fayoum University180
已完成
1 期
Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia GravisMuSK Myasthenia GravisNCT05451212Cabaletta Bio7